C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
This image was generated by AI and may not depict real events.
C4 Therapeutics has expanded its long-term partnership with Roche through a new collaboration agreement focused on discovering and developing degrader-antibody conjugates (DACs) for cancer treatment. The agreement includes a $20 million upfront payment and potential milestone payments of over $1 billion.
C4 Therapeutics and Roche have entered into a collaboration agreement to develop degrader-antibody conjugates (DACs) for cancer treatment. The agreement focuses on two oncology targets, with an option for a third target. C4 Therapeutics will develop degraders with payload properties, while Roche will conjugate payloads to targeted antibodies. The companies will work together to advance research in the DAC modality. C4 Therapeutics will receive a $20 million upfront payment and is eligible for milestone payments. The collaboration aims to develop a new way to treat cancers by combining antibody-drug conjugation and targeted protein degradation.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.